November- FDA approves toripalimab

"The USFDA approval of Toripalimab marks a significant milestone for this rare ...............cancer type. This approval is a first in many ways – first and only immuno Oncology drug(PD1 immune checkpoint inhibitor) to be approved by USFDA for NPC, first Immune checkpoint inhibitor from China to be approved by USFDA, the first NBE in-licensed as part of our broader Innovative products strategy to foray into the Innovative NCE/NBE space. Dr.Reddy’s has partnered with Shanghai Junshi Biosciences for commercialisation of Toripalimab across 21 markets in EM and India. Through this, we are excited to build and strengthen our capabilities across the Innovative asset value chain.”

~Anupama Rao Singh